A press release from the CellAge team.
CellAge Limited (“CellAge”) has raised a seed round backed by Michael Greve´s Kizoo Technology Capital and a group of angel investors.
CellAge, a privately held synthetic biology start-up aiming to develop tools and therapies for age-related diseases, has successfully completed a seed fundraising round. In this round Kizoo Technology Capital and a number of angel investors have joined the effort to develop synthetic promoters which will make senescent cells identification and removal safer and more efficient. To achieve this, CellAge is planning to analyze transcriptional profiles of a wide range of senescent cell types using proprietary algorithm and construct novel promoters from candidate regulatory elements identified in this screen. The joint expertise in senescence, synthetic biology and bioinformatics gives CellAge a unique angle on improving ways how gene therapies could be targeted to senescent cells.
“We are happy to support CellAge on its way towards developing therapies aimed at the molecular and cellular repair of damage caused by the aging process”, says Frank Schueler, Managing Director of Kizoo.
“This is an important step for CellAge in bringing the research program even closer to the reality. We want to thank our advisors and investors for helping us getting here. It is a long road ahead but we are determined to work hard to make this technology benefit everyone. In the end, our sole motivation is to make people healthier and advance ageing research further”, says Mantas Matjusaitis, CEO and co-founder of CellAge.
CellAge expects to bring new tools to the scientific community by 2018 and start working on the senolytic therapy soon after that.
